Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: DUSP2

Summary for DUSP2

Gene information	Gene symbol	DUSP2
	Ensembl ID	ENSG00000158050
	Entrez ID	1844
	Gene name	dual specificity phosphatase 2
	Synonyms	PAC-1
	Gene type	protein_coding
	UniProtAcc	Q05923

Top

Dataset with differentially expressed gene: DUSP2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.862132	7.36e-04
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.277672	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.324778	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.405682	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.500787	3.72e-04
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.629212	2.38e-02
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.497929	2.13e-04
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-1.078	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.714625	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.642877	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.685124	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.403017	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.278094	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.776596	1.58e-35
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.297506	2.75e-13
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.726513	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.52091	1.43e-02
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.8567	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.67409	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.336752	8.41e-45
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.692021	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.250871	5.37e-36
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.679787	1.98e-34
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.397711	2.23e-12
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.394044	5.17e-07
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.265213	8.23e-28
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.258871	3.49e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.7956	5.60e-18
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.856415	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.40649	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	-0.681728	1.48e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.371643	2.56e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.61935	3.58e-08
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.303563	7.47e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.500954	2.80e-45
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.778111	3.00e-20
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	1.4045	1.75e-38
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	0.80585	2.90e-12
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.357947	2.79e-07
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.803205	0.00e+00

Top

Expression of DUSP2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to DUSP2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
DUSP2	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating DUSP2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
DUSP2	hsa-miR-106b-5p	94.7274	NM_004418
DUSP2	hsa-miR-20a-5p	94.7274	NM_004418
DUSP2	hsa-miR-6738-3p	94.6801	NM_004418
DUSP2	hsa-miR-302c-3p	93.8109	NM_004418
DUSP2	hsa-miR-302e	93.8109	NM_004418
DUSP2	hsa-miR-106a-5p	93.0699	NM_004418
DUSP2	hsa-miR-526b-3p	93.0699	NM_004418
DUSP2	hsa-miR-519d-3p	93.0699	NM_004418
DUSP2	hsa-miR-17-5p	93.0699	NM_004418
DUSP2	hsa-miR-20b-5p	93.0699	NM_004418
DUSP2	hsa-miR-93-5p	93.0699	NM_004418
DUSP2	hsa-miR-302d-3p	93.0196	NM_004418
DUSP2	hsa-miR-520b-3p	93.0196	NM_004418
DUSP2	hsa-miR-302b-3p	93.0196	NM_004418
DUSP2	hsa-miR-302a-3p	93.0196	NM_004418
DUSP2	hsa-miR-520a-3p	93.0196	NM_004418
DUSP2	hsa-miR-520c-3p	93.0196	NM_004418
DUSP2	hsa-miR-520e-3p	93.0196	NM_004418
DUSP2	hsa-miR-373-3p	93.0196	NM_004418
DUSP2	hsa-miR-372-3p	93.0196	NM_004418
DUSP2	hsa-miR-520d-3p	93.0196	NM_004418
DUSP2	hsa-miR-544a	90.0851	NM_004418
DUSP2	hsa-miR-12122	88.412	NM_004418
DUSP2	hsa-miR-4796-3p	87.8902	NM_004418
DUSP2	hsa-miR-548ah-5p	84.1479	NM_004418
DUSP2	hsa-miR-3609	84.1479	NM_004418
DUSP2	hsa-miR-410-3p	81.6733	NM_004418

Page: 1

Top

Motifs and transcription factors (TFs) regulating DUSP2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
DUSP2	hocomoco__SOX9_HUMAN.H11MO.1.B	SOX9 (directAnnotation).
DUSP2	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
DUSP2	kznf__ZNF613_Imbeault2017_RP_RCADE	ZNF613 (directAnnotation).
DUSP2	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
DUSP2	tfdimers__MD00011	FOXA1; FOXA2; FOXA3 (directAnnotation).
DUSP2	metacluster_168.16	FOXG1 (inferredBy_Orthology).
DUSP2	taipale__FOXD3_DBD_RTAAAYA	FOXD3 (directAnnotation).
DUSP2	taipale_cyt_meth__LHX6_MTCGTTAN_FL_meth	LHX6 (directAnnotation).
DUSP2	transfac_public__M00266	FOXC2 (inferredBy_Orthology).
DUSP2	hocomoco__FOXP1_HUMAN.H11MO.0.A	FOXP1 (directAnnotation).
DUSP2	metacluster_188.6	DLX6; FOXA1; FOXA1; FOXA2; FOXA2; FOXA3; FOXA3; FOXC1; FOXC1; FOXC2; FOXC2; FOXC2; FOXC2; FOXD2; FOXD3; FOXD3; FOXE1; FOXE1; FOXE1; FOXJ2; FOXJ2; FOXK1; FOXL1; FOXL1; FOXM1; FOXP1; FOXP1; HMG20B; IKZF5; SKI (directAnnotation). FOXD2; FOXF1; FOXJ3; FOXK1; FOXL1; FOXL1 (inferredBy_Orthology).
DUSP2	flyfactorsurvey__fd64A_SANGER_5_FBgn0004895	FOXL1 (inferredBy_Orthology).
DUSP2	transfac_pro__M01216	FOXG1; FOXO1 (directAnnotation).
DUSP2	transfac_pro__M05507	IKZF3 (directAnnotation).
DUSP2	metacluster_77.10	SRY (inferredBy_Orthology).
DUSP2	tfdimers__MD00204	GABPA; NKX2-1 (directAnnotation).
DUSP2	transfac_pro__M05977	ZNF257 (directAnnotation).
DUSP2	metacluster_130.15	ARID5B; ARID5B; BPTF (directAnnotation).
DUSP2	metacluster_79.37	FOXJ3 (inferredBy_Orthology).
DUSP2	transfac_pro__M08883	FOXM1 (directAnnotation).
DUSP2	tfdimers__MD00259	HOXA13; MAFA (directAnnotation).
DUSP2	metacluster_188.5	FOXA1; FOXA2; FOXA2; FOXA3; FOXD3; FOXD3; FOXF1; FOXF1; FOXF1; FOXF1; FOXF2; FOXG1; FOXH1; FOXI1; FOXI1; FOXI1; FOXJ1; FOXJ2; FOXL1; FOXO1; FOXO3; FOXO4; FOXO4; FOXQ1 (directAnnotation). FOXK1; FOXL2 (inferredBy_Orthology).
DUSP2	metacluster_41.38	SOX21 (inferredBy_Orthology).
DUSP2	transfac_pro__M08882	FOXC2 (directAnnotation).
DUSP2	transfac_pro__M04746	E2F1 (directAnnotation).
DUSP2	transfac_pro__M08803	CREM (directAnnotation).
DUSP2	transfac_pro__M05751	ZNF141 (directAnnotation).
DUSP2	transfac_pro__M06941	DDIT3 (directAnnotation).
DUSP2	metacluster_5.1	HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology).
DUSP2	transfac_pro__M05987	ZNF180 (directAnnotation).
DUSP2	transfac_pro__M05744	ZXDC (directAnnotation).
DUSP2	cisbp__M00832	TBX1 (inferredBy_Orthology).
DUSP2	metacluster_155.33	ZNF16; ZNF816 (directAnnotation).
DUSP2	transfac_pro__M06976	PBX4 (directAnnotation).
DUSP2	transfac_pro__M06729	ZNF282 (directAnnotation).
DUSP2	transfac_pro__M04858	THAP1 (directAnnotation).
DUSP2	transfac_pro__M06596	ZNF486 (directAnnotation).
DUSP2	transfac_pro__M05887	ZNF837 (directAnnotation).
DUSP2	transfac_pro__M05304	ZBTB5 (directAnnotation).
DUSP2	taipale_tf_pairs__ETV5_DLX2_RSCGGAANNNNNYAATTA_CAP	DLX2; ETV5 (directAnnotation).
DUSP2	transfac_pro__M06404	ZNF497 (directAnnotation).
DUSP2	transfac_pro__M05915	ZBTB20 (directAnnotation).
DUSP2	dbtfbs__ZKSCAN8_representative_N1	ZKSCAN8 (directAnnotation).
DUSP2	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
DUSP2	metacluster_166.2	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).
DUSP2	swissregulon__hs__ELF2	ELF2 (directAnnotation).
DUSP2	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
DUSP2	taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT	ELK1; HOXA1 (directAnnotation).
DUSP2	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	ETV5; FOXI1 (directAnnotation).
DUSP2	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."